Three steps forward, one step back. With the December filing of three supplemental NDAs for Treakisym, SymBio is demonstrating it is willing to move ahead with its strategic plans despite Astellas' (OTC:ALPMY) decision to withdraw its long-delayed EU application for Treakisym in first-line iNHL. Separately, Baxalta (NYSE:BXLT) announced on 3 March that it would discontinue its development and licensing agreement with Onconova (NASDAQ:ONTX) for rigosertib as of August. Onconova is in discussions with Baxalta; however, it is not clear whether Baxalta will help Onconova obtain alternate funding to complete the trial. Issues with SymBio’s partners may have an impact on the timeframes for both rigosertib and the Treakisym label expansion approvals.
To read the entire report Please click on the pdf File Below